All In Biotech

Drug Trial Radar · NCT06571045

A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

A Randomized, Double-Masked, Multi-Center, 3-Arm Pivotal Phase 2/3 Study to Evaluate The Efficacy and Safety of Intravitreal EYE103 Compared With Intravitreal Ranibizumab (0.5mg) in Participants With Diabetic Macular Edema

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Title says "pivotal". Randomized with 984 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

984

Actual

Start

Aug 7, 2024

Primary completion

Jul 14, 2026

Study completion Aug 14, 2027

Sponsor

Lead sponsor
EyeBiotech Ltd.Industry
Sponsor type
Industry
First posted
Aug 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig (EYE103) in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME) In the first year, all 3 treatment groups will be treated every 4 weeks with either remigromig or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm. Approximately 960 participants will be entered in the study.

Conditions

  • Diabetic Macular Edema (DME)

Interventions

  • RanibizumabDrug

    Ranibizumab is a commercially available anti-VEGF treatment formulated for intravitreal administration for use in patients with diabetic macular edema

  • RemigromigDrug

    Remigromig is a humanized antibody formulated for intravitreal administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Best-Corrected Visual Acuity (BCVA) measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chartTime frame: Baseline and Week 52

Locations

183 sites in 20 countries. Site status is shown where the registry gives one.

  • Scottsdale

    Scottsdale, Arizona

  • Fayetteville, Arkansas

    Fayetteville, Arkansas

  • Springdale, Arkansas

    Springdale, Arkansas

  • Bakersfield, CA

    Bakersfield, California

  • Glendale, CA

    Glendale, California

  • Modesto, CA

    Modesto, California

  • Mountain View, CA

    Mountain View, California

  • Redlands, CA

    Redlands, California

  • Sacramento, CA

    Sacramento, California

  • Sacramento, CA

    Sacramento, California

  • Santa Ana

    Santa Ana, California

  • Colorado Springs, CO

    Colorado Springs, Colorado

  • Denver, Colorado

    Denver, Colorado

  • Danbury, CT

    Danbury, Connecticut

  • Manchester, CT

    Manchester, Connecticut

  • Waterford,CT

    Waterford, Connecticut

  • Deerfield Beach, FL

    Deerfield Beach, Florida

  • Fort Lauderdale, FL

    Fort Lauderdale, Florida

  • Fort Myers,FL

    Fort Myers, Florida

  • Gainesville, FL

    Gainesville, Florida

  • Orlando, Florida

    Orlando, Florida

  • Plantation, FL

    Plantation, Florida

  • Sarasota, FL

    Sarasota, Florida

  • Saint Petersburg, FL

    St. Petersburg, Florida

  • Tallahassee, FL

    Tallahassee, Florida

  • Tampa, FL

    Tampa, Florida

  • Tampa, FL

    Tampa, Florida

  • Winter Haven, FL

    Winter Haven, Florida

  • Lemont, IL

    Lemont, Illinois

  • Springfield, Illinois

    Springfield, Illinois

  • West Des Moines, IA

    West Des Moines, Iowa

  • Lenexa, Kansas

    Lenexa, Kansas

  • Wichita, Kansas

    Wichita, Kansas

  • Portland, Maine

    Portland, Maine

  • Hagerstown, MD

    Hagerstown, Maryland

  • Springfield,MA

    Springfield, Massachusetts

  • Grand Rapids, Michigan

    Grand Rapids, Michigan

  • Minneapolis, MN

    Minneapolis, Minnesota

  • Madison, MS

    Madison, Mississippi

  • Bloomfield, NJ

    Bloomfield, New Jersey

Showing 40 of 183 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.